Paul McCluskey is an experienced executive and has been working as Chairman of tranScrip since it's investment in January 2021.
Paul was part of the MBI team that created Concept Life Sciences (CLS) in 2014, a provider of integrated drug discovery, development, analytical testing and consulting services. The business created a platform for rapid growth, resulting in the completion of three build-up acquisitions. CLS grew into a world leading contract research and testing organisation working closely with clients across the Pharma, Agchem and Environmental sectors. CLS was acquired by a strategic trade buyer in 2018. Paul served as CFO and latterly as CEO.
Prior to CLS, Paul was the CFO at Synexus Clinical Research (Synexus), a clinical research company focussed on the management of later stage clinical trials. He was part of the MBO team that took the business private in 2007 and helped to successfully reposition Synexus as an international business with clinics in 7 countries. Synexus established itself as the global leader in the sector. Paul has also held senior roles with GlaxoSmithKline plc and KPMG’s healthcare consulting team.
He is a Fellow of the Institute of Chartered Accountants in England and Wales.